We consider the comparison of two formulations in terms of average bioequivalence using the 2 × 2 cross-over design. In a bioequivalence study, the primary outcome is a pharmacokinetic measure, such as the area under the plasma concentration by time curve, which is usually assumed to have a lognormal distribution. The criterion typically used for claiming bioequivalence is that the 90% confidence interval for the ratio of the means should lie within the interval (0.80, 1.25), or equivalently the 90% confidence interval for the differences in the means on the natural log scale should be within the interval (-0.2231, 0.2231). We compare the gold standard method for calculation of the sample size based on the non-central t distribution with th...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
This is the peer reviewed version of the following article: Molins, E., Cobo, E., Ocaña, J. Two-stag...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
A generic drug product (test product) is bioequivalent to an innovator product (reference product) w...
In 1992, the US Food and Drug Administration declared that two drugs demonstrate average bioequivale...
[[abstract]]In 1992, the US Food and Drug Administration declared that two drugs demonstrate average...
[[abstract]]In 1992, the US Food and Drug Administration declared that two drugs demonstrate average...
The usual approach to determine bioequivalence for highly variable drugs is scaled average bioequiva...
The usual approach to determine bioequivalence for highly variable drugs is scaled average bioequiva...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
This is the peer reviewed version of the following article: Molins, E., Cobo, E., Ocaña, J. Two-stag...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
[[abstract]]The approval of generic drugs requires the evidence of average bioequivalence (ABE) on b...
A generic drug product (test product) is bioequivalent to an innovator product (reference product) w...
In 1992, the US Food and Drug Administration declared that two drugs demonstrate average bioequivale...
[[abstract]]In 1992, the US Food and Drug Administration declared that two drugs demonstrate average...
[[abstract]]In 1992, the US Food and Drug Administration declared that two drugs demonstrate average...
The usual approach to determine bioequivalence for highly variable drugs is scaled average bioequiva...
The usual approach to determine bioequivalence for highly variable drugs is scaled average bioequiva...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
Statistical criterion for evaluation of individual bioequivalence (IBE) between generic and innovati...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
[[abstract]]Statistical criterion for evaluation of individual bioequivalence (IBE) between generic ...
This is the peer reviewed version of the following article: Molins, E., Cobo, E., Ocaña, J. Two-stag...